ASGCT dispatch: In vivo CAR-T is everywhere, but still preclinical

The American Society of Gene & Cell Therapy's annual meeting highlights the growing interest in in vivo CAR-T therapies, although many developments remain in the preclinical stage. Despite the excitement surrounding genetic medicine, developers are still facing significant challenges in bringing these therapies to market. The event serves as a pivotal moment for stakeholders in the health-biotech sector.